Ultragenyx Pharmaceutical Inc
RARE
Company Profile
Business description
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Contact
60 Leveroni Court
NovatoCA94949
USAT: +1 415 483-8800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,276
Stocks News & Analysis
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
stocks
2 ASX companies with the traits of a long-term winner
Two companies that show promising signs of handsomely rewarding shareholders.
video
Our outlook for 2025
Morningstar Equity Market Strategist Lochlan Halloway discusses his view on what we can expect in markets in 2025.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,506.80 | 41.80 | 0.49% |
| CAC 40 | 7,393.76 | 13.02 | 0.18% |
| DAX 40 | 20,024.66 | 115.52 | 0.58% |
| Dow JONES (US) | 42,392.27 | 151.95 | -0.36% |
| FTSE 100 | 8,260.09 | 87.07 | 1.07% |
| HKSE | 19,811.75 | 188.43 | 0.96% |
| NASDAQ | 19,280.79 | 30.00 | -0.16% |
| Nikkei 225 | 39,894.54 | 386.62 | -0.96% |
| NZX 50 Index | 13,038.86 | 71.88 | -0.55% |
| S&P 500 | 5,868.55 | 13.08 | -0.22% |
| S&P/ASX 200 | 8,243.30 | 42.10 | 0.51% |
| SSE Composite Index | 3,257.52 | 5.04 | -0.15% |